Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients

Transplantation

Volumn 75, Issue 9, 2003, Pages 1551-1555

  Marcucci, Rossella ^a   Zanazzi, Maria ^b   Bertoni, Elisabetta ^b   Rosati, Alberto ^b   Fedi, Sandra ^a   Lenti, Meri ^a   Prisco, Domenico ^a   Castellani, Sergio ^a   Abbate, Rosanna ^a   Salvadori, Maurizio ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AZATHIOPRINE; CYANOCOBALAMIN; CYCLOSPORIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; STEROID; VITAMIN;

ADULT; ARTERY DIAMETER; ARTERY INTIMA; ARTICLE; ATHEROSCLEROSIS; B SCAN; CARDIOVASCULAR RISK; CAROTID ARTERY; CLINICAL TRIAL; COMMON CAROTID ARTERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADULT; ARTERIOSCLEROSIS; CAROTID ARTERIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; FOLIC ACID; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIDOXINE; TUNICA INTIMA; VITAMIN B 12;

EID: 0037910277     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000058810.59825.58     Document Type: Article

References (38)

1. Kasiske BL, Guijarro C, Massy Z, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158.
2. Bostom AG, Gohh RY, Beaulieu AJ, et al. Determinants of fasting plasma total homocysteine levels among chronic stable renal transplant recipients. Transplantation 1999; 68: 257.
3. Bostom AG, Gohh RY, Tsai MY, et al. Excess prevalence of fasting and postmethionine loading hyperhomocysteinemia in stable renal transplant recipients. Arterioscler Thromb Vasc Biol 1997; 17: 1894.
4. Ducloux D, Ruedin C, Gibey R, et al. Prevalence, determinants and clinical significance of hyperhomocysteinemia in renal-transplant recipients. Nephrol Dial Transplant 1998; 13: 2890.
5. Massy ZA, Chadefaux-Vekemans B, Chevalier A, et al. Hyperhomocysteinemia: A significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1994; 9: 1103.
6. Marcucci R, Fedi S, Brunelli T, et al. High cysteine levels in renal transplant recipients. Transplantation 2001; 71: 746.
7. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: A prospective study. J Am Soc Nephrol 2000; 11: 134.
8. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic-acid-based supplements: Meta-analysis of randomised trials. BMJ 1998; 316: 94.
9. Bostom AG, Shemin D, Lapane KL, et al. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49: 147.
10. Bostom AG, Gohh RY, Beaulieu AJ, et al. Treatment of hyperhomocysteinemia in renal transplant recipients: A randomized, placebo-controlled trial. Ann Inter Med 1997; 127: 1089.
11. Barth JD. An update on carotid ultrasound measurement of intima-media thickness. Am J Cardiol 2002; 89 (suppl): 32B.
12. Cheng KS, Mikhailidis DP, Hamilton G, Seifalian AM. A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. Cardiovasc Res 2002; 54: 528.
13. Ubels FL, Terpstra WF, Smit AJ. Carotid intima-media thickness: Influence of drug treatment and clinical implications. Neth J Med 1999; 55: 188.
14. Spence JD. Ultrasound measurement of carotid plaque as a surrogate outcome for coronary artery disease. Am J Cardiol 2002; 89(suppl): 10B.
15. Abbate R, Sardi I, Pepe G, et al. The high prevalence of 5-10 methylenetetrahydrofolate reductase in Italians is not associated to an increased risk for coronary artery disease (CAD). Thromb Haemost 1998; 79: 727.
16. Perna FA, Castaldo P, Ingrosso D, De Santo NG. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin. J Nephrol 1999; 12: 230.
17. Arnadottir M, Berg AL, Hegbrant J, Hultberg B. Influence of haemodialysis on plasma total homocysteine concentration. Nephrol Dial Transplant 1999; 14: 142.
18. Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97: 138.
19. Gupta A, Robinson K. Hyperhomocysteinemia and end-stage renal disease. J Nephrol 1997; 10: 77.
20. Bostom AG, Shemin D, Verhoef P, et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. Arterioscler Thromb Vasc Biol 1997; 17: 2554.
21. Guttormsen AB, Ueland PM, Svarstad E, Refsum H. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997; 52: 492.
22. Arnadottir M, Hultberg B, Vladov V, Nillson-Ehle P, Thysell H. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 1996; 61: 509.
23. Folsom AR, Nieto J, McGovern PG. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms and B vitanuns. The ARIC Study. Circulation 1996; 98: 204.
24. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: A common mutation for methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111.
25. Engbersen AMT, Franken DG, Boers GHJ, Stevens EMB, Trijbels FJM, Blom HJ. Thermolabile MTHFR as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995; 56: 142.
26. Morita H, Taguchi J, Kurihara H, et al. Genetic polymorphism of 5, 10 methylenetetrahydrofolate reductase as a risk factor for coronary artery disease. Circulation 1997; 95: 2032.
27. Gaughan DJ, Kluijtmans LA, Barbaux S, et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis 2001; 157: 451.
28. Chen J, Stampfer MJ, Ma J, et al. Influence of a methionine synthase (D919G) polymorphism on plasma homocysteine and folate levels and relation to risk of myocardial infarction. Atherosclerosis 2001; 154: 667.
29. Dekou V, Gudnason V, Hawe E, Miller GJ, Stansbie D, Humphries SE. Gene-environment and gene-gene interaction in the determination of plasma homocysteine levels in healthy middle-aged men. Thromb Haemost 2001; 85: 67.
30. Peterson JC, Spence DJ. Vitamins and progression of atherosclerosis in hyperhomocysteinemia. Lancet 1998; 351: 263.
31. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345: 1593.
32. Vermeulen EGJ, Stehouwer CDA, Twisk JWR, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on the progression of subclinical atherosclerosis: A randomized, placebo-controlled trial. Lancet 2000; 355: 517.
33. Friedman AN, Rosenberg IH, Selhub J, Levey AS, Bostom AG. Hyperhomocysteinemia in renal transplant recipients. Am J Transplant 2002; 2: 308.
34. Spence DJ. Ultrasound measurement of carotid plaque as a surrogate outcome for coronary artery disease. Am J Cardiol 2002; 89(suppl): 10B.
35. Ames PR, Margarita A, Delgado Alves J, Tommasino C, Iannacone L, Brancaccio V. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 2002; 11: 208.
36. Tsai MY, Arnett DK, Eckfeldt JH, Williams RR, Ellison RC. Plasma homocysteine and its association with carotid intimal-medial wall thickness and prevalent coronary heart disease: NHLBI Family Heart Study. Atherosclerosis 2000; 151: 519.
37. Voutilainen S, Alfthan G, Nyyssonen K, Salonen R, Salonen JT. Association between elevated plasma total homocysteine and increased common carotid artery wall thickness. Ann Med 1998; 30: 300.
38. Cook JW, Yin Q, Malinow MR, Orloff SL. Hyperhomocysteinemia indices accelerated transplant vascular sclerosis in syngeneic and allogeneic rat cardiac transplant. Am J Transplant 2002; 2: 244.